Personalized medicine for cancer cachexia via the ghrelin receptor

IF 12.5 1区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Structural & Molecular Biology Pub Date : 2025-02-14 DOI:10.1038/s41594-025-01496-7

Meng Zhang, Yaxu Wang, M. Madan Babu

引用次数: 0

Abstract

The ghrelin receptor (GHSR1a) is a key target for treating cancer cachexia. A study now reveals the structure of the GHSR1a–miniGq complex bound to the approved drug anamorelin, providing insights into the role of superagonism in cancer cachexia therapy. The comprehensive study represents a framework for personalized treatment strategies.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Structural & Molecular Biology BIOCHEMISTRY & MOLECULAR BIOLOGY-BIOPHYSICS

CiteScore

22.00

自引率

1.80%

发文量

160

审稿时长

3-8 weeks

期刊介绍： Nature Structural & Molecular Biology is a comprehensive platform that combines structural and molecular research. Our journal focuses on exploring the functional and mechanistic aspects of biological processes, emphasizing how molecular components collaborate to achieve a particular function. While structural data can shed light on these insights, our publication does not require them as a prerequisite.